Overview

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

Status:
Completed
Trial end date:
2019-07-26
Target enrollment:
Participant gender:
Summary
This study will be conducted to determine the routes and rates of excretion of radio label arising from 14C-ETX2514 and to characterize metabolites of ETX2514 arising from 14C-ETX2514 administered intravenously in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Entasis Therapeutics